title: Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
abstract: A randomized, crossover study compared the effects of atorvastatin, gemfibrozil and their combination on inflammatory markers in type 2 diabetes. C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), secretory phospholipase A2 (sPLA2), interleukin 8 (IL8), monocyte chemotactic protein 1 (MCP1) and tumor necrosis factor α (TNFα) were measured. Both lipid-lowering drugs had positive, complementary and additive effects on inflammatory markers, which were closely related to baseline inflammatory status.
authors: Endocrinology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors: Ana María
authors: AM
authors: Wägner
authors: Jose Luis
authors: JL
authors: Sánchez-Quesada
authors: Sonia
authors: S
authors: Benítez
authors: Cristina
authors: C
authors: Bancells
authors: Jordi
authors: J
authors: Ordóñez-Llanos
authors: Antonio
authors: A
authors: Pérez
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood; D000368:Aged; D000069059:Atorvastatin; D002097:C-Reactive Protein; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D058607:Fibric Acids / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D054467:Phospholipases A2 / Q000097:blood; D054497:Phospholipases A2, Secretory / Q000097:blood; D011758:Pyrroles / Q000627:therapeutic use
chemical_list: D058607:Fibric Acids; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D002097:C-Reactive Protein; D000069059:Atorvastatin; D054467:Phospholipases A2; D054497:Phospholipases A2, Secretory; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase